Downloads: 85

Files in This Item:
File Description SizeFormat 
20406207221104584.pdf439.51 kBAdobe PDFView/Open
Full metadata record
DC FieldValueLanguage
dc.contributor.authorOnda, Yoshiyukien
dc.contributor.authorKanda, Junyaen
dc.contributor.authorKaneko, Hitomien
dc.contributor.authorShimura, Yujien
dc.contributor.authorFuchida, Shin-Ichien
dc.contributor.authorNakaya, Ayaen
dc.contributor.authorItou, Tomokien
dc.contributor.authorYamamura, Ryosukeen
dc.contributor.authorTanaka, Hirokazuen
dc.contributor.authorShibayama, Hirohikoen
dc.contributor.authorShimazu, Yutakaen
dc.contributor.authorUchiyama, Hitojien
dc.contributor.authorYoshihara, Satoshien
dc.contributor.authorAdachi, Yokoen
dc.contributor.authorMatsuda, Mitsuhiroen
dc.contributor.authorHanamoto, Hitoshien
dc.contributor.authorUoshima, Nobuhikoen
dc.contributor.authorKosugi, Satoruen
dc.contributor.authorOhta, Kensukeen
dc.contributor.authorYagi, Hideoen
dc.contributor.authorKanakura, Yuzuruen
dc.contributor.authorMatsumura, Itaruen
dc.contributor.authorHino, Masayukien
dc.contributor.authorNomura, Shosakuen
dc.contributor.authorShimazaki, Chihiroen
dc.contributor.authorTakaori-Kondo, Akifumien
dc.contributor.authorKuroda, Junyaen
dc.contributor.alternative恩田, 佳幸ja
dc.contributor.alternative諫田, 淳也ja
dc.contributor.alternative島津, 裕ja
dc.contributor.alternative髙折, 晃史ja
dc.date.accessioned2022-10-07T04:58:24Z-
dc.date.available2022-10-07T04:58:24Z-
dc.date.issued2022-
dc.identifier.urihttp://hdl.handle.net/2433/276621-
dc.description.abstractBackground: Little is known about the real-world survival benefits and safety profiles of carfilzomib-lenalidomide-dexamethasone (KRd) and carfilzomib-dexamethasone (Kd). Methods: We performed a retrospective analysis to evaluate their efficacy and safety in 157 patients registered in the Kansai Myeloma Forum database. Results: A total of 107 patients received KRd. Before KRd, 99% of patients had received bortezomib (54% were refractory disease), and 82% had received lenalidomide (57% were refractory disease). The overall response rate (ORR) was 68.2%. The median progression-free survival (PFS) and overall survival (OS) were 8.8 and 29.3 months, respectively. Multivariate analysis showed that reduction of the carfilzomib dose and non-IgG M protein were significantly associated with lower PFS and reduction of the carfilzomib dose and refractoriness to prior bortezomib-based regimens were significantly associated with lower OS. A total of 50 patients received Kd. Before Kd, 96% of patients had received bortezomib (54% were refractory disease). The ORR was 62.0%. The median PFS and OS were 7.1 and 20.9 months, respectively. Based on the multivariate analysis, reduction of the carfilzomib dose and International Staging System Stage III (ISS III) were significantly associated with lower PFS. Grade III or higher adverse events were observed in 48% of KRd cases and 54% of Kd cases. Cardiovascular events, cytopenia, and infections were frequent, and 4 KRd patients died due to heart failure, arrhythmia, cerebral hemorrhage, and pneumonia. Conclusion: Our analysis showed that an adequate dose of carfilzomib is important for achieving the best survival benefits in a real-world setting. Adverse effects after KRd and Kd therapy should also be considered.en
dc.language.isoeng-
dc.publisherSAGE Publicationsen
dc.rights© The Author(s), 2022.en
dc.rightsThis article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage).en
dc.rights.urihttps://creativecommons.org/licenses/by-nc/4.0/-
dc.subjectcarfilzomiben
dc.subjectdexamethasoneen
dc.subjectKden
dc.subjectKRden
dc.subjectlenalidomideen
dc.subjectreal-world efficacy and safetyen
dc.subjectrelapsed/refractory multiple myelomaen
dc.titleReal-world effectiveness and safety analysis of carfilzomib-lenalidomide-dexamethasone and carfilzomib-dexamethasone in relapsed/refractory multiple myeloma: a multicenter retrospective analysisen
dc.typejournal article-
dc.type.niitypeJournal Article-
dc.identifier.jtitleTherapeutic Advances in Hematologyen
dc.identifier.volume13-
dc.relation.doi10.1177/20406207221104584-
dc.textversionpublisher-
dc.identifier.pmid35785245-
dcterms.accessRightsopen access-
dc.identifier.pissn2040-6207-
dc.identifier.eissn2040-6215-
Appears in Collections:Journal Articles

Show simple item record

Export to RefWorks


Export Format: 


This item is licensed under a Creative Commons License Creative Commons